Bempedoic acid

Bempedoic acid
Clinical data
Trade names	Nexletol, Nilemdo
Other names	ESP-55016, ETC-1002
AHFS/Drugs.com	Monograph
MedlinePlus	a620020
License data	US DailyMed: Nexletol;
Pregnancy; category	Contraindicated;
Routes of; administration	By mouth
ATC code	C10AX15 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	99.3%
Metabolism	Glucuronidation
Elimination half-life	21±11 hrs
Excretion	70% urine, 30% feces
Identifiers
	IUPAC name 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid;
CAS Number	738606-46-7;
PubChem CID	10472693;
IUPHAR/BPS	8321;
DrugBank	DB11936;
ChemSpider	8648104;
UNII	1EJ6Z6Q368;
KEGG	D10691;
ChEBI	CHEBI:149601;
ChEMBL	ChEMBL3545313;
CompTox Dashboard (EPA)	DTXSID401027952 ;
ECHA InfoCard	100.238.679
Chemical and physical data
Formula	C19H36O5
Molar mass	344.492 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O;
	InChI InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24); Key:HYHMLYSLQUKXKP-UHFFFAOYSA-N;

Bempedoic acid, sold under the brand name Nexletol among others, is a medication for the treatment of hypercholesterolemia (high blood cholesterol levels).^[2]^[3]

The most common side effects include hyperuricemia (high blood levels of uric acid), pain in arms or legs, and anemia (low red blood cell counts).^[3]

Bempedoic acid blocks an enzyme in the liver called adenosine triphosphate-citrate lyase, which is involved in making cholesterol.^[3]

Bempedoic acid was approved for use in the United States in February 2020, and for use in the European Union in April 2020.^[3]^[5]^[6] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[7]

^ "Nilemdo 180mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 4 September 2020. Retrieved 17 January 2021.
^ ^a ^b ^c "Nexletol- bempedoic acid tablet, film coated". DailyMed. U.S. National Library of Medicine. 10 March 2020. Retrieved 19 March 2020.
^ ^a ^b ^c ^d ^e "Nilemdo EPAR". European Medicines Agency (EMA). 29 January 2020. Retrieved 24 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Nilemdo Product information". Union Register of medicinal products. Retrieved 3 March 2023.
^ "Drug Approval Package: Nexletol". U.S. Food and Drug Administration (FDA). 24 March 2020. Retrieved 17 January 2021.
^ Cite error: The named reference FDA snapshot was invoked but never defined (see the help page).
^ "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Archived from the original on 18 January 2021. Retrieved 17 January 2021.

[1] "Nilemdo 180mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 4 September 2020. Retrieved 17 January 2021.

[Nexletol_FDA_label-2] "Nexletol- bempedoic acid tablet, film coated". DailyMed. U.S. National Library of Medicine. 10 March 2020. Retrieved 19 March 2020.

[Nilemdo_EPAR-3] "Nilemdo EPAR". European Medicines Agency (EMA). 29 January 2020. Retrieved 24 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[4] "Nilemdo Product information". Union Register of medicinal products. Retrieved 3 March 2023.

[FDA_Drug_Approval_Package-5] "Drug Approval Package: Nexletol". U.S. Food and Drug Administration (FDA). 24 March 2020. Retrieved 17 January 2021.

[FDA_snapshot-6] Cite error: The named reference FDA snapshot was invoked but never defined (see the help page).

[7] "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Archived from the original on 18 January 2021. Retrieved 17 January 2021.

[1]

[2]

[3]

[4]

[5]

[6]

[7]